Combining Sintilimab with Chemoradiotherapy for High-risk Nasopharyngeal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This program focuses on patients with high-risk locoregionally advanced nasopharyngeal carcinoma, specifically those staged as T3-4N2-3M0. Participants will undergo three cycles of induction chemotherapy using gemcitabine and cisplatin, followed by concurrent cisplatin-radiation and Sintilimab treatment. After intensity-modulated radiotherapy (IMRT), patients will continue receiving Sintilimab for an additional 11 cycles. The study aims to evaluate the efficacy and safety of this combined treatment approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with histologically confirmed Non-keratinizing nasopharyngeal carcinoma.
2. Tumor staged as III-IVA (AJCC 8th, T3-4N2-3M0).
3. Eastern Cooperative Oncology Group performance status ≤1.
4. Adequate marrow function: neutrocyte count≥1.5×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L.
5. Alanine Aminotransferase (ALT)/Aspartate Aminotransferase (AST) ≤2.5×upper limit of normal (ULN), and bilirubin ≤ 1.5×ULN.
6. Adequate renal function: creatinine clearance rate ≥ 60 ml/min (Cockcroft-Gault formula).
7. Patients must be informed of the investigational nature of this study and give written informed consent.
8. Women of childbearing potential (WOCBP) who are sexually active must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of study drug. Men who are sexually active with WOCBP must be willing to adhere to effective contraception during treatment and for 1 year after the last dose of the study drug.

Exclusion Criteria:

* 1.Age \> 70 or \< 18. 2.Hepatitis B surface antigen (HBsAg) positive and hepatitis B virus DNA \>1×10e3 copies/ml or 200IU/ml 3.Hepatitis C virus (HCV) antibody positive 4.Has active autoimmune disease, except type I diabetes, hypothyroidism treated with replacement therapy, and skin disease that doesn't require systemic treatment.

  5.Has a known history of interstitial lung disease. 6.Has any condition that required systemic corticosteroid (equivalent to prednisone \>10mg/d) or other immunosuppressive therapy within 28 days before informed consent. Patients received systemic corticosteroid equivalent to prednisone ≤10mg/d, inhale or topical corticosteroid will be allowed.

  7.Has received a live vaccine within 30 days before informed consent or will receive a live vaccine in the near future.

  8.Is pregnant or breastfeeding. 9.Has a history of other malignancies except carcinoma in situ, adequately treated non-melanoma skin cancer, and papillary thyroid cancer.

  10.Has known allergy to large molecule protein products or any compound of sintilimab.

  11.Has a known history of human immunodeficiency virus (HIV) infection. 12.Any other condition, including symptomatic heart failure, unstable angina, myocardial infarction, active infection requiring systemic therapy, mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a

Where it's running

• Guangxi Medical University Cancer Hospital
  Nanning, Guangxi, China Recruiting

Study contacts

• Principal investigator: Xiao-Dong Zhu, Doctor — Cancer Hospital of Guangxi Medical University
• Study coordinator: Xiao-Dong Zhu, Doctor
• Email: zhuxiaodong83@163.com
• Phone: 13978873616

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sintilimab + ipilimumab N01 with cetuximab and dabrafenib for MSS BRAF V600E metastatic colorectal cancer

  This trial will test whether combining the immunotherapies sintilimab and ipilimumab N01 with cetuximab and dabrafenib helps people with microsatellite-stable, BRAF V600E metastatic colorectal cancer live longer or have better tumor control.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Beijing, Beijing Municipality and 3 other locations · NCT07506109

• Thiotepa with pirtobrutinib and sintilimab for frail or relapsed/refractory CNS lymphoma

  This treatment combines thiotepa with pirtobrutinib and sintilimab for adults who are frail or whose primary or secondary central nervous system lymphoma has relapsed or not responded to prior therapy.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07416890

• Sintilimab plus bevacizumab biosimilar before surgery for resectable liver cancer

  This trial will test whether giving sintilimab together with a bevacizumab biosimilar before surgery helps people with resectable hepatocellular carcinoma beyond the Milan criteria.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07324824

• Combining PD‑1 immunotherapy (sintilimab) with platinum‑doublet chemotherapy and adaptive radiotherapy for stage III non‑small cell lung cancer

  This study tests whether adding the PD‑1 drug sintilimab to standard platinum‑doublet chemotherapy plus adaptive radiotherapy helps people with unresectable stage III non‑small cell lung cancer.

  Recruiting at 4 sites Phase 2 The Third Xiangya Hospital of Central South University · Changsha, Hunan and 3 other locations · NCT07138755

• Combining low dose radiotherapy with immunotherapy and chemotherapy for lung cancer treatment

  This study is testing whether a combination of low dose radiation, immunotherapy, and chemotherapy can help people with stage II-III non-small cell lung cancer do better before surgery.

  Recruiting Phase 2 Anhui Provincial Cancer Hospital · Hefei, Anhui · NCT06714708

• Using sintilimab after chemoradiotherapy for elderly patients with esophageal cancer

  This study is testing if adding a new treatment called sintilimab after chemotherapy and radiation can help older patients with esophageal cancer live longer and healthier.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06413342

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.